Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Colorectal Neoplasms

Free Subscription 02.03.2020 1 Adv Exp Med Biol 137 Ann Oncol 1 Ann Surg Oncol 1 Br J Cancer 1 Cancer Lett 4 Dis Colon Rectum 2 Gastrointest Endosc 3 Int J Colorectal Dis 1 J Am Coll Surg 4 N Engl J Med 1 Oncology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Adv Exp Med Biol

1. FUNG KY, Nguyen PM, Putoczki TL
   Emerging Roles for Interleukin-18 in the Gastrointestinal Tumor Microenvironment.
   Adv Exp Med Biol. 2020;1240:59-72.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. CASE A, Arif S
   The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation.
   Ann Oncol. 2019;30 Suppl 4:iv14.
   PubMed     Text format    
   
   
3. ARGILES G, Margalef NM, Valladares-Ayerbes M, de Prado JV, et al
   Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC).
   Ann Oncol. 2019;30 Suppl 4:iv135.
   PubMed     Text format    
   
   
4. PIETRANTONIO F, Lobefaro R, Antista M, Miceli R, et al
   A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients.
   Ann Oncol. 2019;30 Suppl 4:iv135.
   PubMed     Text format    
   
   
5. GALON J, Hermitte F, Mlecnik B, Marliot F, et al
   Significant differences in outcome between Immunoscore categories in stage I colon cancer patients.
   Ann Oncol. 2019;30 Suppl 4:iv134.
   PubMed     Text format    
   
   
6. GAMBARO K, Marques M, McNamara S, du Tertre MC, et al
   Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy.
   Ann Oncol. 2019;30 Suppl 4:iv133.
   PubMed     Text format    
   
   
7. ELIZABETH A, Jansen L, Hendrik B, Kloor M, et al
   Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
   Ann Oncol. 2019;30 Suppl 4:iv132.
   PubMed     Text format    
   
   
8. MYER P, Lee J, Madison R, Newberg J, et al
   Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry.
   Ann Oncol. 2019;30 Suppl 4:iv132.
   PubMed     Text format    
   
   
9. WATANABE J, Sato T, Kagawa Y, Oki E, et al
   SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer.
   Ann Oncol. 2019;30 Suppl 4:iv132.
   PubMed     Text format    
   
   
10. PFEIFFER P, Glimelius B, Winther S, Qvortrup C, et al
    Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results.
    Ann Oncol. 2019;30 Suppl 4:iv131.
    PubMed     Text format    
    
    
11. PARIKH A, Van Seventer E, Boland G, Hartwig A, et al
    Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv131.
    PubMed     Text format    
    
    
12. PFEIFFER P, Yilmaz M, Moller S, Zitnjak D, et al
    Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial.
    Ann Oncol. 2019;30 Suppl 4:iv130-iv131.
    PubMed     Text format    
    
    
13. GARRALDA E, Fiedler W, Matos I, Rolling C, et al
    Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.
    Ann Oncol. 2019;30 Suppl 4:iv125.
    PubMed     Text format    
    
    
14. SALEH M, Cassier P, Eberst L, Naik G, et al
    Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study.
    Ann Oncol. 2019;30 Suppl 4:iv124.
    PubMed     Text format    
    
    
15. VAN CUTSEM E, Machiels J, Van den Eynde M, Prenen H, et al
    Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv124-iv125.
    PubMed     Text format    
    
    
16. GEISSLER M, Tannapfel A, Reinacher-Schick A, Martens U, et al
    Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv119-iv120.
    PubMed     Text format    
    
    
17. ANGELIS V, Young T, Vasiliadou I, Hill M, et al
    Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv14.
    PubMed     Text format    
    
    
18. CASADEI GARDINI A, Gelsomino F, Spallanzani A, Tamburini E, et al
    Is there an optimal choice in refractory colorectal cancer? A network meta-analysis.
    Ann Oncol. 2019;30 Suppl 4:iv14.
    PubMed     Text format    
    
    
19. KOPETZ S, Grothey A, Van Cutsem E, Yaeger R, et al
    BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv154.
    PubMed     Text format    
    
    
20. ELBAIOMY M, Waheed A, Elkhodary T
    Prognostic value of lymph node ratio in lymph node-invaded colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv34.
    PubMed     Text format    
    
    
21. CUNHA R, Menezes M, Fernandes R, Oliveira A, et al
    Stage IIa colon cancer: adjuvant chemotherapy in real life.
    Ann Oncol. 2019;30 Suppl 4:iv32.
    PubMed     Text format    
    
    
22. GIULIANI J, Bonetti A
    The onset of grade>/=3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil.
    Ann Oncol. 2019;30 Suppl 4:iv31.
    PubMed     Text format    
    
    
23. LOMBARDI P, Marandino L, De Luca E, Zichi C, et al
    Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018.
    Ann Oncol. 2019;30 Suppl 4:iv29.
    PubMed     Text format    
    
    
24. TILBY M, Escola C, Ellison C, Narramneni L, et al
    Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience.
    Ann Oncol. 2019;30 Suppl 4:iv27.
    PubMed     Text format    
    
    
25. ISHIGURO A, Yuki S, Takahashi N, Shichinohe T, et al
    North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: final analysis (NORTH/HGCSG1003).
    Ann Oncol. 2019;30 Suppl 4:iv24.
    PubMed     Text format    
    
    
26. FERNANDEZ MONTES A, Martinez Lago N, De la Camara Gomez J, Covela Rua M, et al
    FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial.
    Ann Oncol. 2019;30 Suppl 4:iv23-iv24.
    PubMed     Text format    
    
    
27. SFAKIANAKI M, Papadaki C, Tzardi M, Trypaki M, et al
    PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv21-iv22.
    PubMed     Text format    
    
    
28. ZAREV I, Maksimovic M, Ljubisavljevic R, Bozovic M, et al
    Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv21.
    PubMed     Text format    
    
    
29. CHEONG C, Suh K
    Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features.
    Ann Oncol. 2019;30 Suppl 4:iv20.
    PubMed     Text format    
    
    
30. ROSATI G, Cordio S, Reggiardo G, Aprile G, et al
    Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies.
    Ann Oncol. 2019;30 Suppl 4:iv19-iv20.
    PubMed     Text format    
    
    
31. NOGUEIRA-COSTA G, Fernandes I, Guerra-Pereira N, Gameiro R, et al
    Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role.
    Ann Oncol. 2019;30 Suppl 4:iv18.
    PubMed     Text format    
    
    
32. FEDYANIN M, Chekini D, Chubenko V, Tjulandin S, et al
    Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis.
    Ann Oncol. 2019;30 Suppl 4:iv16.
    PubMed     Text format    
    
    
33. PAPAMICHAEL D, Kountourakis P, Papanastasopoulos P, Xenophontos E, et al
    Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years.
    Ann Oncol. 2019;30 Suppl 4:iv16.
    PubMed     Text format    
    
    
34. KOGAN Y, Elishmereni M, Taub E, Agur Z, et al
    (late submission poster) The tumor burden rise at radiological disease progression associates with poor overall survival in advanced colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv155.
    PubMed     Text format    
    
    
35. DUCREUX M, O'Connor J, Dochy E, Fiala-Buskies S, et al
    Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv119.
    PubMed     Text format    
    
    
36. OSTERLUND P, Lamminmaki A, Soveri L, Algars A, et al
    Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study.
    Ann Oncol. 2019;30 Suppl 4:iv119.
    PubMed     Text format    
    
    
37. KIM S, Kim S
    Interleukin-6 induced Lipocalin 2 promotes tumorigenesis from colitis to colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv105-iv106.
    PubMed     Text format    
    
    
38. BERRAD S, Oualla K, Nouiyakh L, Erraichi H, et al
    Survival and prognostic factors for stage II colon cancer.
    Ann Oncol. 2019;30 Suppl 4:iv105.
    PubMed     Text format    
    
    
39. BEKOUACI S, Smaili F
    Are hepatic metastases of colorectal cancer more chemosensitive than other metastatic sites?
    Ann Oncol. 2019;30 Suppl 4:iv104.
    PubMed     Text format    
    
    
40. SHIN R, Park J, Jeong S, Heo S, et al
    Clinicopathologic feature of microsatellite stable early-onset colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv104.
    PubMed     Text format    
    
    
41. BEKOUACI S, Smaili F
    Clinico-epidemiological profile of colorectal cancer in Algerian patients age 40 and under: Alarming increase in incidence.
    Ann Oncol. 2019;30 Suppl 4:iv103-iv104.
    PubMed     Text format    
    
    
42. SIMOES J, Fernandes C, Borges C, Melo R, et al
    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv101.
    PubMed     Text format    
    
    
43. STREICH G, Batagelj E, Dimase F, Martinez D, et al
    Home chemotherapy in colorectal cancer: First experience in Argentina.
    Ann Oncol. 2019;30 Suppl 4:iv101.
    PubMed     Text format    
    
    
44. ELKHOULY E, Gohar S, Abelela D, Fakhry T, et al
    Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv100-iv101.
    PubMed     Text format    
    
    
45. TOPI G, Satapathy S, Dash P, Ehrnstrom R, et al
    High expression of estrogen receptor beta correlates with anti-tumorigenic and anti-proliferative inflammatory proteins in colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv100.
    PubMed     Text format    
    
    
46. RAMIREZ DAFFOS P, Gonzalez-Astorga B, Jimenez E, Rubiales S, et al
    Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities.
    Ann Oncol. 2019;30 Suppl 4:iv10-iv11.
    PubMed     Text format    
    
    
47. MURO K, Uetake H, Tsuchihara K, Shitara K, et al
    PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv10.
    PubMed     Text format    
    
    
48. ZOK J, Radecka B, Adamowicz K, Korniluk J, et al
    Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv10.
    PubMed     Text format    
    
    
49. KRUCHININA M, Gromov A, Prudnikova I, Shashkov M, et al
    Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics.
    Ann Oncol. 2019;30 Suppl 4:iv1.
    PubMed     Text format    
    
    
50. SINGH AV
    Evaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed     Text format    
    
    
51. LEE CL, Toomey S, Farrelly A, Hennessy B, et al
    Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
    Ann Oncol. 2019;30 Suppl 1:i7.
    PubMed     Text format    
    
    
52. CARNERERO CORDOBA L, Gonzalez Cebrian I, Rodriguez Gonzalez C, Gonzalez-Flores E, et al
    Clinical significance of BRAF mutations in colorectal cancer: A retrospective study of one institution in a real-life population.
    Ann Oncol. 2019;30 Suppl 4:iv106.
    PubMed     Text format    
    
    
53. SATAPATHY S, Sjolander A
    15-PGDH regulated PD-1/PD-L1 immune checkpoint blockade immunotherapy in colon cancer is a TNF-alpha dependent phenomenon.
    Ann Oncol. 2019;30 Suppl 4:iv107.
    PubMed     Text format    
    
    
54. HOFHEINZ R, Scholten F, Derigs H, Thaler J, et al
    Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113).
    Ann Oncol. 2019;30 Suppl 4:iv118.
    PubMed     Text format    
    
    
55. ROSSINI D, Pagani F, Pellino A, Dell'Aquila E, et al
    Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis.
    Ann Oncol. 2019;30 Suppl 4:iv118.
    PubMed     Text format    
    
    
56. MAURI G, Kanter K, Fish M, Horick N, et al
    PARP-ness in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv117.
    PubMed     Text format    
    
    
57. DAS R, Ou F, Washburn C, Innocenti F, et al
    Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv116.
    PubMed     Text format    
    
    
58. SALVATORE L, Bria E, Sperduti I, Hinke A, et al
    Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies.
    Ann Oncol. 2019;30 Suppl 4:iv116.
    PubMed     Text format    
    
    
59. CARDONE C, Blauensteiner B, Moreno-Viedma V, Paul M, et al
    Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS.
    Ann Oncol. 2019;30 Suppl 4:iv116.
    PubMed     Text format    
    
    
60. RAIMONDI A, Di Maio M, Peverelli G, Morano F, et al
    Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study.
    Ann Oncol. 2019;30 Suppl 4:iv115.
    PubMed     Text format    
    
    
61. LAM K, Ko J, Chan A, Choi H, et al
    Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv115-iv116.
    PubMed     Text format    
    
    
62. SUNAKAWA Y, Nakamura M, Ishizaki M, Kataoka M, et al
    RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv114.
    PubMed     Text format    
    
    
63. ROSSINI D, Sbrana A, Bergamo F, Manai C, et al
    Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies.
    Ann Oncol. 2019;30 Suppl 4:iv114-iv115.
    PubMed     Text format    
    
    
64. OSTERMAN E, Mezheyeuski A, Sjoblom T, Glimelius B, et al
    Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort.
    Ann Oncol. 2019;30 Suppl 4:iv113.
    PubMed     Text format    
    
    
65. VIEITEZ DE PRADO J, Encinas Garcia S, Grande Pulido E, Sanchez Nieto R, et al
    Cost of metastatic colorectal cancer drugs per month of life gained in Spain.
    Ann Oncol. 2019;30 Suppl 4:iv11.
    PubMed     Text format    
    
    
66. RADWI A, Asiri I, Asiri M, Khudhayri A, et al
    Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv11-iv12.
    PubMed     Text format    
    
    
67. GROTHEY A, Yaeger R, Paez D, Tabernero J, et al
    ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).
    Ann Oncol. 2019;30 Suppl 4:iv109.
    PubMed     Text format    
    
    
68. SGHAIER S, Rachdi H, Mejri N, Graja B, et al
    How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases.
    Ann Oncol. 2019;30 Suppl 4:iv108-iv109.
    PubMed     Text format    
    
    
69. CAVIC M, Vidosavljevic M, Radulovic S, Grahovac J, et al
    Nischarin expression in colon cancer.
    Ann Oncol. 2019;30 Suppl 1:i7-i8.
    PubMed     Text format    
    
    
70. GHIDINI M, Hahne J, Senti C, Lampis A, et al
    Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
    Ann Oncol. 2019;30 Suppl 4:iv34-iv35.
    PubMed     Text format    
    
    
71. BRIDGEWATER J
    Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?
    Ann Oncol. 2020 Feb 14. pii: S0923-7534(20)35948.
    PubMed     Text format    
    
    
72. D'ARCANGELO M, Buonerba C, Avallone A, Dazzi C, et al
    The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study.
    Ann Oncol. 2019;30 Suppl 4:iv87-iv88.
    PubMed     Text format    
    
    
73. BENSI M, Calegari M, Basso M, Orlandi A, et al
    Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study).
    Ann Oncol. 2019;30 Suppl 4:iv87.
    PubMed     Text format    
    
    
74. RODRIGUEZ-COBOS J, Vinal D, Poves C, Fernandez-Acenero M, et al
    DeltaNp73 and Delta133p53 in liquid biopsy as early diagnostic markers for colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv86-iv87.
    PubMed     Text format    
    
    
75. BEN NASR S, Alibi S, Msekni I, Zribi A, et al
    Role of TILS in predicting evolution of metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv85.
    PubMed     Text format    
    
    
76. MIHAYLOVA Z, Ivanova D, Mihaylova G, Tasinov O, et al
    Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease.
    Ann Oncol. 2019;30 Suppl 4:iv81-iv82.
    PubMed     Text format    
    
    
77. PRETTA A, Lai E, Liscia N, Impera V, et al
    Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience.
    Ann Oncol. 2019;30 Suppl 4:iv81.
    PubMed     Text format    
    
    
78. ZHENG Q, Peng P
    Long non-coding RNA Linc00525 is an unfavorable prognostic factor and regulates proliferation and apoptosis in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv8.
    PubMed     Text format    
    
    
79. BASILE D, Pelizzari G, Di Nardo P, Corvaja C, et al
    The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA).
    Ann Oncol. 2019;30 Suppl 4:iv79.
    PubMed     Text format    
    
    
80. VAN CUTSEM E, Shitara K, Deng W, Vaury A, et al
    Gevokizumab, an interleukin-1beta (IL-1beta) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): "first-in-cancer" phase Ib study.
    Ann Oncol. 2019;30 Suppl 4:iv77-iv78.
    PubMed     Text format    
    
    
81. RUIZ-VOZMEDIANO J, Gutierrez-Martinez A, Postigo-Martin P, Cruz-Fernandez M, et al
    Efficacy of a therapeutic exercise program on autonomic nervous system function, cardiac function and functional capacity in colorectal cancer survivors: a randomized controlled pilot study.
    Ann Oncol. 2019;30 Suppl 4:iv77.
    PubMed     Text format    
    
    
82. ODENY T, Farha N, Hildebrand H, Allen J, et al
    Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv73.
    PubMed     Text format    
    
    
83. CALDERILLO-RUIZ G, Heredia D, Lopez H, Carbajal B, et al
    Retroperitoneal lymph node metastases as a prognosis factor in overall survival in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv72.
    PubMed     Text format    
    
    
84. NAGASAKA T, Tanioka H, Nyuya A, Katata Y, et al
    Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors.
    Ann Oncol. 2019;30 Suppl 4:iv71.
    PubMed     Text format    
    
    
85. MARINHO J, Neto E, Leao I, Silva J, et al
    Liquid biopsy for RAS mutational status analysis in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv69-iv70.
    PubMed     Text format    
    
    
86. BEN KRIDIS W, Mnif A, Khmiri S, Feki J, et al
    Right-sided versus left-sided metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv68.
    PubMed     Text format    
    
    
87. TOMAS T, Nogueira-Costa G, Eiriz I, Vitorino M, et al
    Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: Real-world data of 13 oncological centers in Portugal.
    Ann Oncol. 2019;30 Suppl 4:iv88.
    PubMed     Text format    
    
    
88. MARAVIC Z, Benedict A, Komlos K, Lemmens L, et al
    Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey.
    Ann Oncol. 2019;30 Suppl 4:iv90-iv91.
    PubMed     Text format    
    
    
89. SALEM ME, Yin J, Goldberg RM, Pederson LD, et al
    Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35924.
    PubMed     Text format     Abstract available
    
    
90. KOLESNIK O, Lukashenko A, Ostapenko Y, Chorna N, et al
    Laparoscopic liver resection in metastatic colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv99.
    PubMed     Text format    
    
    
91. GUETTITI TOUNSI H, Wider D, Ben Ayed I, Habbachi A, et al
    Colorectal cancer in young Tunisian patients: clinical, histopathological and RAS testing data.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed     Text format    
    
    
92. DASH P, Topi G, Sjolander A
    To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed     Text format    
    
    
93. ALIANE H, Ghomari-Bezzar S
    The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv98.
    PubMed     Text format    
    
    
94. LUKASHENKO A, Kolesnik O, Chorna N, Ostapenko Y, et al
    Simultaneous lungs and liver resections in metastatic colorectal cancer patients.
    Ann Oncol. 2019;30 Suppl 4:iv98-iv99.
    PubMed     Text format    
    
    
95. ALIANE H, Ghomari-Bezzar S
    Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX.
    Ann Oncol. 2019;30 Suppl 4:iv97.
    PubMed     Text format    
    
    
96. AYARI J, Karrit S, Guesmi R, Zribi A, et al
    Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A prospective study in 60 patients in Tunisia.
    Ann Oncol. 2019;30 Suppl 4:iv97.
    PubMed     Text format    
    
    
97. DIAZ C, Calderillo-Ruiz G, Ramos-Ramirez M, Herrera M, et al
    Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population.
    Ann Oncol. 2019;30 Suppl 4:iv95.
    PubMed     Text format    
    
    
98. ROSSAT S, Lefevre M, Le Berre N, Dorel M, et al
    Turnaround time < 7 days with a fully automated assay for RAS mutations in metastatic colorectal cancer: a pilot project in real-life conditions.
    Ann Oncol. 2019;30 Suppl 4:iv95.
    PubMed     Text format    
    
    
99. JAVED H, Faisal M, Khan J, Anwar H, et al
    Higher expression of ERBB2, KRAS and down-regulation of APC, NF1 genes in colorectal cancer.
    Ann Oncol. 2019;30 Suppl 4:iv94.
    PubMed     Text format    
    
    
100. HISAMATSU A, Ikusue T, Toshima H, Kobayashi K, et al
     Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy.
     Ann Oncol. 2019;30 Suppl 4:iv93.
     PubMed     Text format    
     
     
101. BELAID I, Khechine W, Saad A, Fki A, et al
     Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia.
     Ann Oncol. 2019;30 Suppl 4:iv93-iv94.
     PubMed     Text format    
     
     
102. VITALE P, Zanaletti N, Vitiello P, Martinelli E, et al
     Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data.
     Ann Oncol. 2019;30 Suppl 4:iv91.
     PubMed     Text format    
     
     
103. DE FALCO V, Vitiello P, Giunta E, Ciardiello D, et al
     Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience.
     Ann Oncol. 2019;30 Suppl 4:iv90.
     PubMed     Text format    
     
     
104. CIPRIANO A, Tavares A, Soares A, Mesquita A, et al
     The importance of laterality in colorectal cancer predicting response to therapeutics - retrospective study evaluating differences between right and left colon in stage IV colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv67-iv68.
     PubMed     Text format    
     
     
105. KIM C, Kim W, Han Y, Kim J, et al
     Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv35.
     PubMed     Text format    
     
     
106. JAROSZ M, Rychlik E
     Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland.
     Ann Oncol. 2019;30 Suppl 4:iv50.
     PubMed     Text format    
     
     
107. PARK Y, Lee K, Lee J, Oh S, et al
     Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv5.
     PubMed     Text format    
     
     
108. FORMICA V, Nardecchia A, Morelli C, Lucchetti J, et al
     A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv48.
     PubMed     Text format    
     
     
109. MARTINEZ-LAGO N, Carmona Campos M, Gonzalez Villarroel P, Salgado Fernandez M, et al
     Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen.
     Ann Oncol. 2019;30 Suppl 4:iv42-iv43.
     PubMed     Text format    
     
     
110. BOUDINAR F, Larbaoui B
     Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases.
     Ann Oncol. 2019;30 Suppl 4:iv41-iv42.
     PubMed     Text format    
     
     
111. ABDALLAH E, Souzae Silva V, Aguiar S Jr, Takahashi R, et al
     Circulating tumor cells levels correlate with carcinoembryonic antigen in patients with high-risk colon cancer who experienced disease progression.
     Ann Oncol. 2019;30 Suppl 4:iv41.
     PubMed     Text format    
     
     
112. CALDERILLO-RUIZ G, Lopez H, Herrera M, Trejo E, et al
     Obesity and hyperglycemia as a bad prognosis factor for recurrence and survival in colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv40-iv41.
     PubMed     Text format    
     
     
113. CALDERILLO-RUIZ G, Lopez H, Padilla A, Diaz C, et al
     Surgery specialization as a prognostic factor in colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv40.
     PubMed     Text format    
     
     
114. CALDERILLO-RUIZ G, Lopez H, Diaz C, Ruiz-Garcia E, et al
     Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III.
     Ann Oncol. 2019;30 Suppl 4:iv39.
     PubMed     Text format    
     
     
115. RICCI V, Falletta A, Granetto C, Paccagnella M, et al
     Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib.
     Ann Oncol. 2019;30 Suppl 4:iv38.
     PubMed     Text format    
     
     
116. CALEGARI M, Zurlo I, Basso M, Orlandi A, et al
     Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study).
     Ann Oncol. 2019;30 Suppl 4:iv37-iv38.
     PubMed     Text format    
     
     
117. VERMORKEN J, Cervantes A, Morsing P, Johansson K, et al
     A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer.
     Ann Oncol. 2019;30 Suppl 4:iv36.
     PubMed     Text format    
     
     
118. SUN G, Gao P, Jia J, Zhang L, et al
     Efficacy and safety of apatinib for metastatic colorectal cancer in standard therapy failure.
     Ann Oncol. 2019;30 Suppl 4:iv36.
     PubMed     Text format    
     
     
119. FEDYANIN M, Chubenko V, Belonogov A, Beluhin S, et al
     Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study.
     Ann Oncol. 2019;30 Suppl 4:iv35.
     PubMed     Text format    
     
     
120. YU H, Yao X, Meng X
     A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism.
     Ann Oncol. 2019;30 Suppl 4:iv35-iv36.
     PubMed     Text format    
     
     
121. DE TORO CARMENA M, Ortega Moran L, Garcia Adrian S, Castanon Lopez C, et al
     Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients.
     Ann Oncol. 2019;30 Suppl 4:iv51-iv52.
     PubMed     Text format    
     
     
122. KR A, P SS, Kumar C R
     Complete peritonectomy versus selective peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes.
     Ann Oncol. 2019;30 Suppl 4:iv52.
     PubMed     Text format    
     
     
123. NAZARIAN A, Sureshbabu S, Berman N, Wolf D, et al
     RENCA macrobead therapy (RMB): A biological-systems approach to metastatic colorectal cancer [U.S. FDA BB-IND 10091].
     Ann Oncol. 2019;30 Suppl 4:iv64.
     PubMed     Text format    
     
     
124. BURZ C, Bojan A, Balacescu L, Lisencu C, et al
     Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv63-iv64.
     PubMed     Text format    
     
     
125. SANCHEZ-CAMACHO A, Herrero Rivera D, Carrasco I, Limon M, et al
     Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution.
     Ann Oncol. 2019;30 Suppl 4:iv62.
     PubMed     Text format    
     
     
126. PREJAC J, Kekez D, Belev B, Plestina S, et al
     Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer: a single-centre retrospective cohort analysis of 186 patients.
     Ann Oncol. 2019;30 Suppl 4:iv62.
     PubMed     Text format    
     
     
127. TAMPAKIS A, Tampaki E, Nonni A, Patsouris E, et al
     L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease.
     Ann Oncol. 2019;30 Suppl 4:iv60.
     PubMed     Text format    
     
     
128. FORNER S, Summers J, Hill M, Mikropoulos C, et al
     Which patients on chemotherapy for colorectal cancer should be anticoagulated?
     Ann Oncol. 2019;30 Suppl 4:iv6.
     PubMed     Text format    
     
     
129. WONG S, Chiang C, Yeung S, Lee S, et al
     The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastases.
     Ann Oncol. 2019;30 Suppl 4:iv58.
     PubMed     Text format    
     
     
130. BOUSAHBA A, Behourah Z
     Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab.
     Ann Oncol. 2019;30 Suppl 4:iv56.
     PubMed     Text format    
     
     
131. BAE J, Kye B, Lee Y, Lee I, et al
     Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer patients.
     Ann Oncol. 2019;30 Suppl 4:iv56.
     PubMed     Text format    
     
     
132. GRIDNEV D, Trandofilov M, Zhevelyuk A, Islamova D, et al
     The role of combined treatment of metastatic colorectal cancer in patients with liver metastases.
     Ann Oncol. 2019;30 Suppl 4:iv55.
     PubMed     Text format    
     
     
133. KR A, P SS, Kumar C R
     Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer.
     Ann Oncol. 2019;30 Suppl 4:iv54.
     PubMed     Text format    
     
     
134. KR A, P SS, Kumar C R
     Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
     Ann Oncol. 2019;30 Suppl 4:iv54.
     PubMed     Text format    
     
     
135. DUARTE S, Grilo I, Ladeira K, Pimenta J, et al
     Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences.
     Ann Oncol. 2019;30 Suppl 4:iv53.
     PubMed     Text format    
     
     
136. JAROSZ M, Rychlik E
     Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland.
     Ann Oncol. 2019;30 Suppl 4:iv53.
     PubMed     Text format    
     
     
137. APARICIO J, Virgili A, Capdevila J, Munoz Boza F, et al
     Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).
     Ann Oncol. 2019;30 Suppl 4:iv52.
     PubMed     Text format    
     
     
138. OMRCEN T, Katic A, Tomic S, Eterovic D, et al
     Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?
     Ann Oncol. 2019;30 Suppl 4:iv65.
     PubMed     Text format    
     
     

     
     Ann Surg Oncol

139. ZAFAR SN, Hu CY, Snyder RA, Cuddy A, et al
     Predicting Risk of Recurrence After Colorectal Cancer Surgery in the United States: An Analysis of a Special Commission on Cancer National Study.
     Ann Surg Oncol. 2020 Feb 20. pii: 10.1245/s10434-020-08238.
     PubMed     Text format     Abstract available
     
     

     
     Br J Cancer

140. BANDO H, Kagawa Y, Kato T, Akagi K, et al
     Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
     Br J Cancer. 2020 Feb 25. pii: 10.1038/s41416-020-0766.
     PubMed     Text format     Abstract available
     
     

     
     Cancer Lett

141. QIN Y, Shembrey C, Smith J, Paquet-Fifield S, et al
     Laminin 521 enhances self-renewal via Stat3 activation and promotes tumor progression in Colorectal Cancer.
     Cancer Lett. 2020 Feb 24. pii: S0304-3835(20)30095.
     PubMed     Text format     Abstract available
     
     

     
     Dis Colon Rectum

142. DE ROO AC, Morris AM, Vu JV, Schuman AD, et al
     Characteristics of Patients Seeking Second Opinions at a Multidisciplinary Colorectal Cancer Clinic.
     Dis Colon Rectum. 2020 Feb 26. doi: 10.1097/DCR.0000000000001647.
     PubMed     Text format     Abstract available
     
     
143. BEDRIKOVETSKI S, Dudi-Venkata NN, Kroon HM, Moore JW, et al
     Outcomes of Minimally Invasive Versus Open Proctectomy for Rectal Cancer: A Propensity-Matched Analysis of Bi-National Colorectal Cancer Audit Data.
     Dis Colon Rectum. 2020 Feb 26. doi: 10.1097/DCR.0000000000001654.
     PubMed     Text format     Abstract available
     
     
144. HIYOSHI Y, Yamasaki A, Shono T, Miyamoto Y, et al
     Laparoscopic and Endoscopic Cooperative Surgery for Rectal GI Stromal Tumor.
     Dis Colon Rectum. 2020;63:116.
     PubMed     Text format    
     
     
145. HAMEED I, Aggarwal P, Weiser MR
     Robotic Right Hemicolectomy With Complete Mesocolic Excision and D3 Lymph Node Dissection.
     Dis Colon Rectum. 2020;63:115.
     PubMed     Text format    
     
     

     
     Gastrointest Endosc

146. GIJSBERS KM, Post Z, Schrauwen RWM, Tang TJ, et al
     Low value of second-look endoscopy in detecting residual colorectal cancer after endoscopic removal.
     Gastrointest Endosc. 2020 Feb 24. pii: S0016-5107(20)30140.
     PubMed     Text format     Abstract available
     
     
147. LAM AY, Li Y, Gregory DL, Prinz J, et al
     Association between improved adenoma detection rate and interval colorectal cancer rates after a quality improvement program.
     Gastrointest Endosc. 2020 Feb 21. pii: S0016-5107(20)30143.
     PubMed     Text format     Abstract available
     
     

     
     Int J Colorectal Dis

148. LI Y, Monzo M, Moreno I, Martinez-Rodenas F, et al
     KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
     Int J Colorectal Dis. 2020 Feb 22. pii: 10.1007/s00384-020-03538.
     PubMed     Text format     Abstract available
     
     
149. WANG Y, Xiao J, Zhao Y, Du S, et al
     Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences.
     Int J Colorectal Dis. 2020 Feb 25. pii: 10.1007/s00384-020-03539.
     PubMed     Text format     Abstract available
     
     
150. TOMINAGA T, Nonaka T, Shiraisi T, Hamada K, et al
     Factors related to short-term outcomes and delayed systemic treatment following primary tumor resection for asymptomatic stage IV colorectal cancer.
     Int J Colorectal Dis. 2020 Feb 26. pii: 10.1007/s00384-020-03550.
     PubMed     Text format     Abstract available
     
     

     
     J Am Coll Surg

151. HAYES-JORDAN AA, Sandler G, Malakord S, Xiao LC, et al
     Colon Cancer in Patients Under 25 Years Old: A Different Disease?
     J Am Coll Surg. 2020 Feb 14. pii: S1072-7515(20)30167.
     PubMed     Text format     Abstract available
     
     

     
     N Engl J Med

152. KOPETZ S, Grothey A, Tabernero J
     Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply.
     N Engl J Med. 2020;382:877-878.
     PubMed     Text format    
     
     
153. PIETRANTONIO F
     Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
     N Engl J Med. 2020;382:876-877.
     PubMed     Text format    
     
     
154. PRASAD V
     Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
     N Engl J Med. 2020;382:876.
     PubMed     Text format    
     
     
155. SHARMA V, Vanidassane I
     Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
     N Engl J Med. 2020;382:876.
     PubMed     Text format    
     
     

     
     Oncology

156. SATO Y, Inaba Y, Aramaki T, Sone M, et al
     Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study.
     Oncology. 2020 Feb 24:1-6. doi: 10.1159/000505520.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: